VistaGen Therapeutics to Present at Noble Financial Capital Markets Ninth Annual Equity Conference

SOUTH SAN FRANCISCO, CA--(Marketwire - Jan 22, 2013) - VistaGen Therapeutics, Inc. ( OTCBB : VSTA ) ( OTCQB : VSTA ), a biotechnology company applying stem cell technology for drug rescue, predictive toxicology and drug metabolism screening, today announced that Shawn K. Singh, CEO of VistaGen, will present at Noble Financial Capital Markets' Ninth Annual Equity Conference.

Mr. Singh will discuss VistaGen's progress and unique opportunities to apply its stem cell technology platform, Human Clinical Trials in a Test Tube, for drug rescue, predictive toxicology and drug metabolism screening. Mr. Singh's presentation will be delivered at 12:30 pm EST on Wednesday, January 23, 2013, at the Hard Rock Hotel in Hollywood, Florida.

Webcast Information: At the time of the presentation, a live audio and video webcast of Mr. Singh's presentation and a copy of the presentation materials will be available on VistaGen's website at http://www.vistagen.com and Noble Financial's website at http://www.noblefcm.com. Investors and analysts should register approximately 10 minutes prior to the start of the presentation to ensure timely access. Viewing the presentation will require Microsoft Silverlight (a free download is available from the presentation link).

About VistaGen Therapeutics

VistaGen is a biotechnology company applying human pluripotent stem cell technology for drug rescue, predictive toxicology and drug metabolism screening. VistaGen's drug rescue activities combine its human pluripotent stem cell technology platform, Human Clinical Trials in a Test Tube, with modern medicinal chemistry to generate novel, safer chemical variants (Drug Rescue Variants) of once-promising small molecule drug candidates. These are drug candidates discontinued by pharmaceutical companies, the U.S. National Institutes of Health (NIH) or university laboratories, after substantial investment in discovery and development, due to heart or liver toxicity or metabolism issues. VistaGen uses its pluripotent stem cell technology to generate early indications, or predictions, of how humans will ultimately respond to new drug candidates before they are ever tested in humans, bringing human biology to the front end of the drug development process.

Additionally, VistaGen's small molecule drug candidate, AV-101, is completing Phase 1 development for treatment of neuropathic pain. Neuropathic pain, a serious and chronic condition causing pain after an injury or disease of the peripheral or central nervous system, affects millions of people worldwide. To date, VistaGen has been awarded over $8.5 million from the NIH for development of AV-101.

Visit VistaGen at http://www.VistaGen.com, follow VistaGen at http://www.twitter.com/VistaGen or view VistaGen's Facebook page at http://www.facebook.com/VistaGen

About Noble Financial

Noble Financial Capital Markets was established in 1984 and is an equity research driven, full-service, investment banking boutique focused on life sciences, technology and media, emerging growth, companies. The company has offices in New York, Boston, New Jersey, Los Angeles, and Boca Raton, FL. In addition to non-deal road shows and sector-specific conferences throughout the year, Noble Financial hosts its large format annual equity conference in January in South Florida featuring 120 - 150 presenting companies from across North America and total attendance of close to 600.

To learn more about Noble Financial Capital Markets, visit http://www.noblefcm.com

See the original post:
VistaGen Therapeutics to Present at Noble Financial Capital Markets Ninth Annual Equity Conference